FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...
0001100397 false 0001100397 2023-01-13 2023-01-13 iso4217:USD xbrli:shares...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESSEffective Date:December 12, 2022...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A...
Filed Pursuant to Rule 424(b)(3) Registration No. 333-268586 DATED December 12, 2022 ...
0001100397 false --10-31 0001100397 2022-12-01 2022-12-01 iso4217:USD...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K...
0001100397 false 0001100397 2022-10-18 2022-10-18 iso4217:USD xbrli:shares...
0001100397 false --10-31 Q3
0001100397 false 0001100397 2022-06-24 2022-06-24 iso4217:USD xbrli:shares...
0001100397 true S-1/A
0001100397 false --10-31 Q2...
Advaxis, Inc., (OTCQB: ADXS and ADXSD), a leader in developing the next generation of immunotherapies for cancer and infectious diseases...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.